Events

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

SHERIDAN, WYOMING - December 3, 2025 - Solar Solutions Düsseldorf 2025 is set to reinforce North Rhine-Westphalia's role as a high-potential market for renewables, bringing more than 250 exhibitors and a tightly focused B2B audience together under one roof to drive solar, storage, EV charging and green HVAC deployment in Germany's most populous state.

A growing regional platform for solar and smart energy

On Wednesday 3 December and Thursday 4 December 2025, Messe Düsseldorf will again host Solar Solutions Düsseldorf as the central platform for renewable energy in North Rhine-Westphalia. The exhibition continues to scale, with more than 250 exhibitors now spanning 27,050 square meters across two halls, reflecting both supply-side momentum and the demand from installers, planners, energy consultants and other sustainability professionals.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh has introduced its new IM Cxx01CE A3 color multifunction series, positioning the IM C2501CE, IM C3501CE and IM C5501CE as a new sustainability benchmark for office print fleets by combining high reuse rates, lower CO₂ footprint and upgraded security with cloud-ready workflows.

Circular-economy design with high reuse and lower CO₂ footprint

Developed explicitly with circular-economy principles in mind, the new IM Cxx01CE models are manufactured using over 86% reused components and deliver a CO₂ footprint reduced by around 50% compared to comparable multifunction systems. By building on existing hardware resources and refreshing them with the latest security and performance elements, Ricoh enables customers to pursue sustainability targets while maintaining familiar functionality and reliability.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh and Neat have signed a global partnership agreement to deliver integrated, high-end audiovisual solutions for modern workplaces worldwide, combining Neat's AI-driven video devices with Ricoh's AV Managed Services to enhance hybrid collaboration and workplace experience.

Master-level alliance to scale premium meeting experiences

Under the agreement, Neat, a global leader in professional AV and innovative video technology, and Ricoh, a global leading AV integrator, will collaborate at the highest tier of Neat's Global Partner Program-the Mastery level. The partnership is designed to expand Ricoh's portfolio of high-end meeting room solutions and make Neat-powered spaces more accessible across enterprises of all sizes.

SHERIDAN, WYOMING - December 2, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is restructuring its largest site in Wiesloch-Walldorf, appointing long-time manager Orhan Bekyigit as plant director alongside his existing role as site head, in a move designed to sharpen competitiveness, streamline operations and support growth in international markets.

Strategic realignment at Heidelberg's largest production hub

The Wiesloch-Walldorf campus, with around 3,800 employees, is HEIDELBERG's biggest location worldwide and a central pillar of its global manufacturing and technology network. The new setup brings plant management and central site functions under one leadership, with Bekyigit now responsible for both operational execution and cross-site coordination.

SHERIDAN, WYOMING - December 2, 2025 - More than 3,000 print service providers worldwide are now using the cloud-based HEIDELBERG Customer Portal as a digital control center for their end-to-end production, underscoring how system integration and workflow automation are becoming decisive competitive factors in the global print and packaging industry.

Cloud platform becomes a digital command center for print plants

Three years after launch, Heidelberger Druckmaschinen AG's (HEIDELBERG) customer portal is evolving into a central hub for managing production, service and commercial processes. Over 7,000 individual users are actively leveraging the platform to digitalize and automate their operations, with a clear focus on improving efficiency, transparency and sustainability.

SHERIDAN, WYOMING - December 2, 2025 - Swiss communications provider rubmedia has commissioned a compact, highly automated Heidelberg digital print line at its new site in Köniz near Bern, combining a Jetfire 50 inkjet system, a Versafire LV toner press and integrated workflow software to industrialize personalized short-run production.

Digital production line anchors new Köniz facility

With around 35 employees, rubmedia positions itself as a media house focused on creative communication solutions for service providers, industry, associations and political customers. As part of an internal transformation project linked to its relocation, the company rethought its production strategy and installed a tightly integrated digital line designed for efficiency, quality and automation.

SHERIDAN, WYOMING - December 2, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) is reporting a significantly more profitable first half of its 2025/2026 financial year, with revenue growth, a doubling of EBITDA and improving cash flow underscoring the impact of its restructuring program and strategic focus on packaging, label and digital print.

Stronger top line and sharply improved margins

In the six months from April 1 to September 30, 2025, HEIDELBERG grew revenue to €985 million, around 8% above the prior-year period's €915 million. Europe and Asia were the main regional growth engines, while the second quarter contributed €519 million, up from €466 million in the first quarter despite negative currency effects of roughly €12 million versus the prior-year quarter.

SHERIDAN, WYOMING - December 2, 2025 - Roche has secured FDA 510(k) clearance with a CLIA waiver and CE IVDR certification for its first point-of-care test to diagnose Bordetella infections, providing primary care and emergency clinicians with PCR-accurate results in just 15 minutes to help control whooping cough and related diseases.

Fast, PCR-accurate diagnosis at the point of care

Running on the cobas® liat system, Roche's new assay delivers lab-quality PCR results in GP offices and emergency rooms within a standard consultation. The 15-minute turnaround allows physicians to move from suspicion to definitive diagnosis immediately, supporting timely antibiotic prescribing that can prevent severe complications and reduce onward transmission.

SHERIDAN, WYOMING - December 2, 2025 - Roche has reported landmark Phase III results for its oral selective estrogen receptor degrader (SERD) giredestrant, positioning the candidate as a potential new standard of care in early-stage ER-positive, HER2-negative breast cancer after a pivotal trial showed superior invasive disease-free survival versus standard endocrine therapy.

First oral SERD to show superior invasive disease-free survival

The Phase III lidERA Breast Cancer study evaluated adjuvant giredestrant against standard-of-care endocrine monotherapy in more than 4,100 patients with medium- or high-risk stage I-III ER-positive, HER2-negative early breast cancer. At a pre-planned interim analysis, the trial met its primary endpoint: giredestrant delivered a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy.

SHERIDAN, WYOMING - December 2, 2025 - Roche is re-entering the frontline of Alzheimer's disease drug development, after new Phase I/II data showed its next-generation antibody trontinemab cleared amyloid plaques below the threshold of positivity in the vast majority of treated patients while keeping key safety signals under tight control.

Early Brainshuttle data show deep amyloid clearance

In the ongoing Brainshuttle AD Phase I/II study, 92% of patients treated with trontinemab achieved amyloid levels below 24 centiloids, the PET scan threshold commonly used to define amyloid positivity. The data, presented at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, mark one of the strongest plaque-clearing signals yet seen in a mid-stage program.

SHERIDAN, WYOMING - December 2, 2025 - A leaked memo from FDA vaccine chief Vinay Prasad alleging that COVID-19 vaccines caused the deaths of 10 children has triggered a sharp backlash from scientific experts and investors, underscoring deep tensions inside U.S. vaccine regulation and adding fresh volatility for mRNA players Moderna and BioNTech.

An internal memo with external market consequences

In a six-page document titled "Deaths in children due to COVID-19 vaccines and CBER's path forward," Center for Biologics Evaluation and Research head Vinay Prasad claimed that an internal investigation had identified 10 child deaths "linked" to COVID-19 vaccination, based on reports in the Vaccine Adverse Events Reporting System (VAERS). The memo, published by The Washington Post, did not provide specific data, case details or manufacturer names.

SHERIDAN, WYOMING - December 2, 2025 - Imvax is moving its autologous glioblastoma immunotherapy IGV-001 toward the FDA, despite a missed primary endpoint in Phase IIb, betting that a six-month overall survival benefit and a novel "synergistic" treatment concept will resonate in a setting where outcomes have barely budged in two decades.

Phase IIb data highlight survival benefit despite PFS miss

In a mid-stage trial of 99 patients with newly diagnosed glioblastoma, Imvax evaluated IGV-001, a biologic-device combination, against placebo. While the study did not achieve its primary endpoint of improving progression-free survival, the company reported a median overall survival of 20.3 months in the treatment arm-around six months longer than in the control group.

SHERIDAN, WYOMING - December 2, 2025 - After years of volatility in Alzheimer's R&D, Roche's re-emergence with positive early data for trontinemab is reshaping expectations for the next competitive cycle in disease-modifying therapies, signaling that big pharma is not done pushing for better outcomes in this high-risk, high-need market.

From Aduhelm's fallout to a more mature Alzheimer's market

The modern Alzheimer's era was defined-some would say scarred-by the 2021 approval of Biogen and Eisai's Aduhelm, a controversial and costly monoclonal antibody that ultimately failed to deliver convincing clinical benefit and was later withdrawn. The backlash damaged Biogen's reputation and, for a time, cast doubt on the entire amyloid-directed approach, raising questions about regulatory standards and payer willingness to back expensive, marginally effective therapies.

SHERIDAN, WYOMING - December 2, 2025 - A series of FDA findings at Novo Nordisk's Bloomington, Indiana, fill/finish facility is forcing biotechs to rethink their commercial manufacturing strategies, with Regeneron and Scholar Rock now accelerating alternative capacity plans to break regulatory logjams linked to the ex-Catalent site.

FDA scrutiny at Novo's Bloomington site triggers CRLs

The Bloomington plant, one of three former Catalent sites Novo acquired for $11 billion to support surging GLP-1 demand, has become a bottleneck rather than a release valve for some of its biopharma customers. As a CDMO hub, the facility provided fill/finish services for a range of partners, but repeated quality issues have resulted in an Official Action Indicated (OAI) classification and multiple complete response letters (CRLs) from the FDA.

SHERIDAN, WYOMING - December 2, 2025 - As bispecifics, antibody-drug conjugates (ADCs), protein degraders and AI-designed mini-proteins move rapidly into clinical development, discovery teams are confronting a new bottleneck: not target ideas, but the practical engineering and scalable production of molecules that strain conventional biologics workflows.

From monoclonals to a radically more complex biologics toolbox

Monoclonal antibodies still anchor the biologics market, with more than 160 FDA approvals and a dominant share of global drug revenues. But the modality mix is shifting fast. More than 200 ADCs are now in clinical stages, bispecific approvals have climbed to 19 with sales above $12 billion in 2024, and regulators are increasingly supportive of novel protein formats.

SHERIDAN, WYOMING - December 2, 2025 - Microbial fermentation is moving back to the center of biologics manufacturing strategy, and contract development and manufacturing organizations (CDMOs) like AGC Biologics are under pressure to turn the platform's greatest strength-speed-into a reproducible, industrial-scale advantage.

Microbial fermentation's resurgence - and its speed problem

Microbial systems have long been valued for fast, efficient production of biologics, and they are now seeing renewed interest for a new generation of therapies. Yet the same speed that makes microbial fermentation attractive also makes it unforgiving. Typical production runs last around 48 hours, leaving very little time to diagnose and correct process deviations once a run is underway.

SHERIDAN, WYOMING - December 2, 2025 - As several large pharmas pull back from cell therapy, a core group of biopharma players is doubling down on CAR T and next-generation approaches, positioning themselves to capture long-term value in oncology and autoimmune disease even as near-term sentiment cools.

Big pharma exits reshape expectations, not potential

Over the past year, the cell therapy field has seen a string of high-profile retreats. Takeda halted new investments in the modality and is offloading its pipeline and platforms after more than eight years of heavy spending. Novo Nordisk followed by terminating all cell therapy work, including a type 1 diabetes program, with nearly 250 roles cut. Belgian biotech Galapagos also shut down its cell therapy business after failing to find a buyer.

SHERIDAN, WYOMING - December 2, 2025 - A wave of first-in-class hereditary angioedema (HAE) therapies is reshaping the U.S. Biotech & Research landscape, but questions remain over how quickly clinicians and patients will adopt these options in an already well-served rare disease market.

New approvals expand hereditary angioedema treatment choices

The HAE pipeline has accelerated dramatically, moving from basic C1 esterase inhibitors to sophisticated RNA-targeting and gene-editing approaches. The disease's life-threatening swelling attacks, including airway involvement, have long justified investment in both acute and prophylactic care, with the first FDA-approved preventive and on-demand therapies arriving in 2008 and 2009.